Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : Amarin
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership aims to distribute and commercialize Vazkepa (icosapent ethyl), approved and commercialized in a number of global markets, including the U.S. and European markets, across 10 countries, including nine in Southeast Asia and South Korea.
Brand Name : Vazkepa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 31, 2023
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : Amarin
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tadalafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Recipient : Eli Lilly
Deal Size : $57.5 million
Deal Type : Acquisition
Lotus Acquires Cialis® (Tadalafil) in Taiwan From Lilly
Details : Cialis® (tadalafil), is indicated for the treatment of erectile dysfunction and benign prostatic hyperplasia, and Cialis® is positioned as the top 2 brand product for erectile dysfunction treatment with high brand loyalty.
Brand Name : Cialis
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 22, 2022
Lead Product(s) : Tadalafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Recipient : Eli Lilly
Deal Size : $57.5 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
